Prostaxen 60 mg | Generic Apalutamide by Everest Pharmaceuticals

Description

Dr. Daria KwaśniewskaESMO Certified Consultant Medical Oncologist

Reviewed June 2026

⚠ Prescription required. For informational purposes only. Meds For Cancer is a Named Patient Program facilitator — not a retail pharmacy. A valid oncologist prescription is mandatory before any order is processed.

Is Prostaxen 60 mg right for your situation?

Review these criteria with your oncologist before enquiring

✔ You may be a candidate if

✓Non-metastatic castration-resistant prostate cancer (nmCRPC), high-risk for metastasis
✓Metastatic castration-sensitive prostate cancer (mCSPC), in combination with ADT
✓Already receiving, or planning to receive, a GnRH analog or have had a bilateral orchiectomy
✓Need a WHO-GMP generic alternative to Erleada® (Janssen)

✖ May NOT be suitable if

✗History of seizures, brain injury, recent stroke, brain tumours, or brain metastases
✗Not receiving concurrent androgen deprivation therapy (GnRH analog or orchiectomy)
✗Significant cardiovascular disease without close monitoring
✗Not for use in women — this medicine is for male prostate cancer patients only

Check Availability & Pricing

Prescription required · Named Patient Program · Worldwide shipping

💬 WhatsApp: +880 130 449 8958 ✉ Email: info@medsforcancer.com

🛡 WHO-GMP Certified · Prescription verified · Express dispatch

What is Prostaxen 60 mg?

Prostaxen 60 mg is a generic formulation of Apalutamide — a next-generation androgen receptor inhibitor — manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP certified conditions in Bangladesh. Each tablet contains 60 mg of apalutamide, the same active molecule found in Erleada® (Janssen), and is dispensed under the Named Patient Program.

Prostaxen is used exclusively in men with prostate cancer, always alongside ongoing androgen deprivation therapy (either a GnRH analog injection or surgical orchiectomy) — it is not a standalone treatment.

Generic name	Apalutamide
Reference brand	Erleada® (Janssen)
Manufacturer	Everest Pharmaceuticals Ltd.
Standard	WHO-GMP Certified
Drug class	Androgen Receptor Inhibitor
Dosage form	Tablet — 60 mg
Pack size	120 tablets per pack (30-day supply)
Route	Oral · once daily, with or without food
Prescription	Required — oncologist/urologist only

How Apalutamide Works

Prostate cancer cells depend on androgens (male hormones, mainly testosterone) binding to androgen receptors to grow. Standard androgen deprivation therapy lowers testosterone levels, but some cancer cells find ways to keep signalling through the androgen receptor despite low testosterone — this is “castration resistance.”

Apalutamide directly blocks the androgen receptor itself — it competitively inhibits androgen binding, prevents the receptor from moving into the cell nucleus, blocks its DNA binding, and impedes androgen-receptor-mediated gene transcription. This shuts down the growth signal at the receptor level, working even when testosterone is already suppressed by ADT. The pivotal SPARTAN trial showed apalutamide significantly delayed metastasis in nmCRPC, and the TITAN trial demonstrated improved overall survival in mCSPC.

Side Effects

Apalutamide carries an important seizure risk warning that determines who can safely take this medication.

Common · Usually Manageable

Fatigue
Hypertension
Rash
Diarrhoea, nausea
Weight loss, decreased appetite
Hot flashes
Joint pain

Serious · Report Immediately

Seizures (contraindicated in patients with seizure history/risk factors)
Falls and fractures
Ischaemic heart disease
Severe skin reactions

⚠ Seek emergency care immediately for:

A seizure of any kind — discontinue Prostaxen permanently and seek immediate medical attention
Chest pain, breathlessness, or signs of heart problems
A fall resulting in injury

How to Take Prostaxen 60 mg

Standard dose: 240 mg (four 60 mg tablets) taken together, once daily — not as separate doses spread through the day. Taken with or without food, alongside ongoing androgen deprivation therapy.

1
All four tablets together, once daily — this is one single 240 mg dose, not four separate doses through the day.
2
Swallow tablets whole with water. Do not crush or chew.
3
If you miss a dose, skip it and resume your normal schedule the following day — do not take a missed dose late in the day or double up.
4
Continue your GnRH analog or maintain post-orchiectomy status — Prostaxen is not effective as a standalone treatment.
5
Storage: room temperature, original packaging, out of reach of children.

Frequently Asked Questions

Is Prostaxen taken as one dose of 240 mg or as separate 60 mg doses through the day?

Prostaxen is taken as a single dose of 240 mg (four 60 mg tablets swallowed together) once daily — not as four separate 60 mg doses spread throughout the day. Take all four tablets at the same time, once a day.

Why is there a seizure warning with Prostaxen?

In clinical trials, seizures occurred in a small percentage of patients taking apalutamide. Because of this, apalutamide is not recommended for patients with a history of seizures or predisposing factors such as brain injury, recent stroke, primary brain tumours, or brain metastases. If a seizure occurs during treatment, apalutamide must be permanently discontinued.

Do I still need my testosterone-lowering injections while taking Prostaxen?

Yes. Apalutamide must be used alongside ongoing androgen deprivation therapy — either a GnRH analog injection or surgical orchiectomy. It is not effective as a standalone treatment and does not replace testosterone suppression.

Can women take Prostaxen?

No. Prostaxen (apalutamide) is specifically indicated for prostate cancer, which occurs only in men. It has no approved use in women.

How do I order Prostaxen through Meds For Cancer?

Contact us via WhatsApp (+880 130 449 8958) or email (info@medsforcancer.com) with your oncologist or urologist’s prescription. Our team will verify the prescription, confirm availability and pricing, and arrange secure international shipping under the Named Patient Program.

🛡 Named Patient Program — Regulatory Framework

Meds For Cancer operates as a Named Patient Program (NPP) facilitator. WHO-GMP certified medicines are made available to individual patients with a confirmed medical need and a valid prescription, in countries where the branded product is unavailable or unaffordable.

Clinical References

Smith MR, et al. Apalutamide treatment and metastasis-free survival in prostate cancer (SPARTAN). NEJM 2018;378:1408–1418.
Chi KN, et al. Apalutamide for metastatic castration-sensitive prostate cancer (TITAN). NEJM 2019;381:13–24.
FDA Prescribing Information: Erleada (apalutamide). Janssen, 2023.